| abstract |
Synergistic anti-inflammatory drug for application to the skin. This medicinal product contains in combination, in a pharmaceutical vehicle acceptable for administration to the skin, at least one corticosteroid in a proportion of between 0.0005 and 0.5% by weight and at least one β-agonist. This medication is intended more particularly for the treatment of dermatitis and dermatoses, psoriasis, epidermolytic hyperkeratoses, lamellar ichthyosis, pemphigus or gout. |